Oxford Works With Drugmakers to Reverse 90% Trial Failure RateMakiko Kitamura
By the time Pfizer Inc., Johnson and Johnson, Elan Corp. and Eli Lilly & Co. announced their experimental medicines had shown limited benefit for Alzheimer’s patients in late-stage testing, the industry and academia had spent more than $30 billion researching amyloid plaque in the brain. Now they are working together to prevent such failures.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.